NT-proBNP point-of-care testing for predicting mortality in end-stage renal disease: A survival analysis

This study examines the predictive value of elevated N-terminal-pro brain natriuretic peptide (NT-pro BNP) levels for mortality among patients with end-stage renal disease (ESRD). Data from 768 ESRD patients, excluding those with cancer or lost follow-up, were analyzed using Kaplan–Meier curves and Cox proportional hazards models over three years. Results indicated that patients with very high NT-pro BNP levels had shorter average survival times and a significantly higher risk of mortality (hazard ratio 1.43). Advanced age, ICU admission, and comorbidities like cerebrovascular diseases and chronic obstructive pulmonary disease also contributed to increased mortality risks. Thus, elevated NT-pro BNP is an independent risk factor for mortality in ESRD patients. •High NT-pro BNP levels, advanced age, and prolonged hospital stay increase mortality risk in end-stage renal disease (ESRD) patients.•Very high serum NT-pro BNP concentrations reduce 3-year survival in ESRD patients.•Elevated serum NT-pro BNP levels independently predict mortality (Hazard Ratio 1.43, 95% Confidence Interval: 1.06-1.92).•Advanced age, intensive care unit (ICU) admission, cerebrovascular accident (CVA), and chronic obstructive pulmonary disease (COPD) significantly increase mortality risk in ESRD patients.